Clinical Trial Update: Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of Atenativ (human plasma-derived antithrombin) in heparin-resistant patients undergoing cardiac surgery with ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Antithrombin Deficiency

Drugs mentioned

• Atenativ

Snippet

Sponsor: Octapharma | Conditions: Acquired Antithrombin Deficiency | Phase 3 | Status: RECRUITING